| Entry |
|
|---|
| Name |
Cyclophosphamide (USP);
Cyclophosphamide hydrate (JP18);
Cytoxan (TN);
Neosar (TN) |
|---|
| Product |
|
|---|
| Generic |
CYCLOPHOSPHAMIDE (Alembic Pharmaceuticals Limited), CYCLOPHOSPHAMIDE (Alembic Pharmaceuticals), CYCLOPHOSPHAMIDE (Amneal Pharmaceuticals LLC), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (BluePoint Laboratories), CYCLOPHOSPHAMIDE (Cipla USA), CYCLOPHOSPHAMIDE (Civica), CYCLOPHOSPHAMIDE (Fresenius Kabi USA), CYCLOPHOSPHAMIDE (Long Grove Pharmaceuticals), CYCLOPHOSPHAMIDE (NorthStar Rx LLC), CYCLOPHOSPHAMIDE (NorthStar RxLLC), CYCLOPHOSPHAMIDE (STI Pharma LLC), CYCLOPHOSPHAMIDE (Sagent Pharmaceuticals), CYCLOPHOSPHAMIDE (Sandoz), CYCLOPHOSPHAMIDE (XGen Pharmaceuticals DJB) |
|---|
| Formula |
C7H15Cl2N2O2P. H2O
|
|---|
| Exact mass |
278.0354
|
|---|
| Mol weight |
279.1012
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4211 |
| Product (DG00675): | D00287<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Alkylating agent, Immunosuppressant |
|---|
| Disease |
Hodgkin's disease [DS: H00007] Burkitt lymphoma [DS: H00008] Multiple myeloma [DS: H00010] Chronic lymphocytic leukemia [DS: H00005] Acute myelogenous leukemia [DS: H00003] Acute lymphoblastic (stem-cell) leukemia [DS: H00001 H00002] Mycosis fungoides [DS: H01463] Neuroblastoma [DS: H00043] Adenocarcinoma of the ovary [DS: H00027] Retinoblastoma [DS: H01513] Carcinoma of the breast [DS: H00031] Nephrotic syndrome [DS: H01657] |
|---|
| Comment |
Active form of prodrug: 4-Hydroxycyclophosphamide [CPD: C07643]
|
|---|
| Target |
DNA |
|---|
| Metabolism |
Enzyme: CYP2B6 [HSA: 1555]; CYP2A6 [HSA: 1548], CYP2C8 [HSA: 1558], CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07040 | Antineoplastics - alkylating agents |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
L01AA Nitrogen mustard analogues
L01AA01 Cyclophosphamide
D00287 Cyclophosphamide (USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Alkylating Agents
Cyclophosphamide
D00287 Cyclophosphamide (USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
421 Alkylating agents
4211 Chlorethylamines
D00287 Cyclophosphamide (USP); Cyclophosphamide hydrate (JP18)
Drug groups [BR:br08330]
Antineoplastic
DG01677 Alkylating agent
DG01678 Nitrogen mustard analog
DG01720 Isophosphoramide mustard analog
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
Metabolizing enzyme substrate
DG01638 CYP2A6 substrate
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
DG02919 CYP2B6 substrate
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
DG02918 CYP2C8 substrate
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
DG01642 CYP2C9 substrate
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00675 Cyclophosphamide
D00287 Cyclophosphamide
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00287 Cyclophosphamide hydrate
D00287 Cyclophosphamide tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00287
Drug groups [BR:br08330]
Antineoplastic
DG01677 Alkylating agent
DG01678 Nitrogen mustard analog
DG01720 Isophosphoramide mustard analog
DG00675 Cyclophosphamide
Metabolizing enzyme substrate
DG01638 CYP2A6 substrate
DG00675 Cyclophosphamide
DG02919 CYP2B6 substrate
DG00675 Cyclophosphamide
DG02918 CYP2C8 substrate
DG00675 Cyclophosphamide
DG01642 CYP2C9 substrate
DG00675 Cyclophosphamide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00675 Cyclophosphamide
Prodrugs [br08324.html]
DG00675
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 15
1 P1a P 22.9658 -14.9801
2 N1c N 22.9715 -13.5156
3 N1x N 24.0976 -15.6395
4 O2x O 21.8279 -15.6395
5 O3b O 21.6997 -14.2450
6 C1b C 21.6646 -12.8388
7 C1b C 24.2027 -12.7220
8 C1x C 24.0976 -16.9523
9 C1x C 21.8279 -16.9523
10 C1b C 20.4335 -13.6264
11 C1b C 25.5096 -13.3990
12 C1x C 22.9658 -17.5999
13 X Cl 19.1265 -12.9613
14 X Cl 26.7467 -12.6054
15 O0 O 27.7975 -15.3471
BOND 14
1 1 2 1
2 1 3 1
3 1 4 1
4 1 5 2
5 2 6 1
6 2 7 1
7 3 8 1
8 4 9 1
9 6 10 1
10 7 11 1
11 8 12 1
12 10 13 1
13 11 14 1
14 9 12 1
|
|---|
